|
|
Prioritizing and Characterizing T Cell-Relevant Genetic Variants Associated with Autoimmune Diseases |
| 5K22AI153648-02 |
|
NIAID |
2022 |
|
|
Accessible FSHD diagnostics through epigenetic analysis |
| 1R21AR080518-01 |
|
NIAMS |
2022 |
|
|
Foundations for a Phase 1 Clinical Trial ofCell-based Therapy for Duchenne Muscular Dystrophy |
| 1R34AR081536-01 |
|
NIAMS |
2022 |
|
|
Genetic and epigenetic mechanisms of FSHD pathogenesis |
| 2R01AR071287-06 |
|
NIAMS |
2022 |
|
|
Unicondylar Resurfacing in an Ovine Osteoarthritis Disease Model |
| 2SB1AR066439-04A1 |
|
NIAMS |
2022 |
|
|
Clinical and Translational Studies in Muscle Disease |
| 5K24AR073317-05 |
|
NIAMS |
2022 |
|
|
D4Z4 Coding Transcripts and FSHD |
| 5R01AR045203-22 |
|
NIAMS |
2022 |
|
|
Characterization of the Insulin to Autophagy Pathway in Muscles |
| 5R01AR057352-13 |
|
NIAMS |
2022 |
|
|
SMCHD1 Pathways as Candidate Targets for FSHD |
| 5R01AR066248-09 |
|
NIAMS |
2022 |
|
|
Massively-parallel functional interrogation of genetic variation in LGMD-associated sarcoglycan genes |
| 5R21AR078942-02 |
|
NIAMS |
2022 |